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Five-year results of endovascular treatment with
the Gore TAG device compared with open repair
of thoracic aortic aneurysms
Michel S. Makaroun, MD,a Ellen D. Dillavou, MD,a Grayson H. Wheatley, MD,b and
Richard P. Cambria, MD,c for the Gore TAG Investigators, Pittsburgh, Pa; Phoenix, Ariz; and Boston, Mass
Objectives: Report the results of a phase II multicenter, prospective trial comparing endovascular treatment of descending
thoracic aneurysm (TEVAR) with the TAG device to surgical controls after 5 years of follow-up.
Methods: The Gore TAG trial compared the TAG endograft patients (n 140) with standard open surgical controls (n
94) with enrollment from September of 1999 to May of 2001. An additional 51 patients were enrolled in 2003 after
revision of the endograft. Follow-up consisted of patient visits, computed tomography (CT) scans and x-rays at 1, 6, and
12 months and yearly. Significant sac size change was defined as >5 mm increase or decrease from the 1 month baseline
measurement. Migration was defined as >10 mm cranial or caudal movement of the device inside the aorta. Significance
was determined as P < .05.
Results:At 5 years, aneurysm-related mortality was lower for TAG patients at 2.8% compared with open controls at 11.7%
(P  .008). No differences in all-cause mortality were noted, with 68% of TAG patients and 67% of open controls
surviving to 5 years (P  .43). Major adverse events at 5 years were significantly reduced in the TAG group; 57.9% vs
78.7% (P  .001). Endoleaks in the TAG group decreased from 8.1% at 1 month to 4.3% at 5 years. Five TAG patients
have undergone major aneurysm-related re-interventions at 5 years (3.6%), including one arch aneurysm repair for type
1 endoleak and migration, one open conversion and five endovascular procedures for endoleaks in three patients. There
were fewer secondary procedures not directly related to aneurysm repair in the TAG vs the open repair group at 5 years,
15.0% vs 31.9%, (P .01). For TAG patients, sac size at 60months decreased in 50% and increased in 19% compared with
the 1-month baseline. Comparison with the modified low-porosity device at 24 months showed sac increase in 12.9% of
original vs 2.9% in modified grafts (P .11). At 5 years, there have been no ruptures, one migration, no collapse, and 20
instances of fracture in 19 patients, all before the revision of the TAG graft.
Conclusions: In anatomically suitable patients, TAG treatment of thoracic aneurysms is superior to surgical repair at 5
years. Although sac enlargement is concerning, early modified device results indicate this issue may be resolved. (J Vasc
Surg 2008;47:912-8.)Descending thoracic aneurysm (DTA) repaired by the
traditional open surgical procedure has long been recog-
nized as having high morbidity and mortality, even in
centers of excellence.1,2 Thoracic endografting has been
introduced as a means to exclude thoracic aneurysms with
morbidity and mortality equal to or less than traditional
surgical approaches.3-8 Early reports of thoracic endovas-
cular aneurysm repair (TEVAR) have been favorable,3-8
even when high-risk patients were included.6,7 The Gore
TAG (W. L. Gore & Associates, Flagstaff, Ariz) device is
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912currently the only thoracic endoprosthesis approved by the
FDA for commercial use in the treatment of DTA. Early
results of the regulatory trial have been reported previ-
ously.3,4 Despite the excellent short-term results of
TEVAR, there is concern for morbidity related to late inter-
ventions and prosthesis failure. This report details the results
of the Gore TAG phase II multicenter trial at 5 years after
DTA treatment either with the TAG device or open repair.
The primary aims of this nationwide multicenter device
trial were to evaluate the safety and efficacy of the TAG
endoprosthesis in comparison with open surgical repair as
treatment for descending thoracic aortic aneurysms at 1
year, with follow-up scheduled to reach 5 years. Safety was
determined by comparing the occurrence of major adverse
events between the two treatment groups. Efficacy was mea-
sured by the incidence of major device-related events that
required intervention. Secondary endpoints of the study were
comparisons of the early clinical parameters of blood loss,
ICU, andhospital stays and time to return to normal activities.
METHODS
Details of study methods as well as inclusion and exclu-
sion criteria have been previously described.3,4 Briefly, the
Gore TAG pivotal trial was a multicenter, prospective,
nonrandomized phase II study that recruited surgical can-
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2001. One hundred forty endovascular patients were en-
rolled. Ninety-four patients with DTA treated by open
surgery were used as a control group. Of the 94 open
surgical control patients, 44 were concurrent subjects and
50 were historic controls from the enrolling institutions.
Details on the two populations have been previously pub-
lished.3 The groups were not significantly different on
preoperative comorbidities or presentation other than
there were more symptomatic aneurysm patients in the
open surgical group (38% vs 21%, P  .007), and there
were marginally more patients with cardiac histories in the
TAG group (49% vs 36%, P  .06) In May of 2001,
fractures of the longitudinal spine of the TAG graft were
noted. The device was modified by eliminating the longi-
tudinal wire and introducing a new stronger and less porous
polytetrafluoroethylene (PTFE) material.4 From January
2004 to June 2004, an additional 51 TEVAR patients were
enrolled in a confirmatory TAG arm using the modified
device, which is the currently marketed device.
Patients with DTA of at least twice the diameter of the
normal thoracic aorta and with 2 cm of nonaneurysmal
neck for sealing distal to the left carotid artery and proximal
to the celiac artery were eligible for endovascular treatment.
TAG devices ranged from 26 to 40 mm in diameter. Open
repair was performed according to local protocols at the
participating institutions. The extent of the open repair
could not extend more proximally than the left carotid
artery and more distally than the celiac axis. There were no
mandates regarding use of spinal cord protection strategies
or use of left heart bypass. High-risk patients, including
those with dissection, ruptures, mycotic aneurysms, and
trauma were excluded, as were medically high-risk pa-
tients.3,4 Follow-up exams, four-view chest x-rays and spi-
ral computed tomography (CT) scans were performed at 1,
6, and 12 months and yearly thereafter. These assessments
were performed at 3 months if an endoleak was present.
Five-year follow-up was concluded for all available patients
in August of 2006.
Adverse events. Major adverse events (MAE) as de-
fined per Sacks criteria,9 were reported by the study sites
and verified by clinical events coordinators. MAEs were
those that resulted in a prolongation of treatment, new
hospitalization, major disability, or death.Major andminor
adverse events were adjudicated by a clinical events com-
mittee. Aneurysm-related deaths were those deaths which
occurred in hospital or within 30 days of the initial proce-
dure or any reinterventions, or a death due to the aneurysm
or the treatment device. Pre and postoperative DTA mea-
surements and endoleak assessments were performed at the
study sites. Significant sac size change was defined as 5
mm change of the largest diameter of the aneurysm from
the baseline 1-month measurement. Migration was defined
as a graft shift10 mm either cranial or caudal in the aorta.
Statistical analysis. Methods of statistical comparison
have been previously described.3,4 Kaplan-Meier curves
and log-rank tests were used to construct survival curves,
judge significance and track events over time. 2 and theFisher exact test were used to compare nominal data. Contin-
uous variables were comparedwith 2-sample t test in a normal
distribution or the Wilcoxon rank sum test in a non-normal
distribution. P .05 was considered significant.
RESULTS
Two hundred thirty-four patients were treated for de-
scending thoracic aneurysms in the pivotal TAG trial and
underwent either thoracic endografting (n 140) or stan-
dard open repair (n  94). One hundred thirty-seven of
140 patients (98%) successfully received the TAG device in
the pivotal trial, with three access failures. An additional 51
patients were enrolled in the confirmatory arm of the TAG
trial after revision of the device with a follow-up of 2 years.
Mortality. Aneurysm-related mortality was concen-
trated in the early follow-up period with no late deaths
related to rupture or reinterventions in either group. In up
to 66 months after DTA repair, there have been four
aneurysm-related deaths (2.8%) in the TAG group, and 11
aneurysm-related deaths (11.7%) in the open surgical
group (P .008). In the TAG cohort, three of these deaths
were within the original hospitalization, resulting form
stroke, cardiac causes, and sepsis. One later death occurred
2months after TAG placement when the patient was found
to have an aorto-esophageal fistula. He underwent success-
ful conversion but suffered a respiratory arrest and anoxic
brain injury on postoperative day 13. In the open surgical
group, deaths were due to respiratory failure (n 6), stroke
(n  3), cardiac causes (n  1), and aorto-esophageal
fistula (n 1). All deaths occurred within the first year after
treatment. The probability of freedom from aneurysm-
related death was significantly higher (P .01) in the TAG
endograft arm vs surgical controls 5 years after treatment
1 year 2  years 3 years 4 years 5 years
95% C.I. 
TAG
.931, .993 .931, .993 .931, .993 .931, .993 .931, .993
95% C.I. 
Control
.822, .949 .822, .949 .822, .949 .822, .949 .822, .949
Fig 1. Freedom from aneurysm-related death to 5 years.(Fig 1). The aneurysm-related survival advantage was clearly
Fig 2. Freedom from all-cause mortality 5 years after DTA.
aortic aneurysm.
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that there were no late deaths related to endoleak, stent
fracture, material fatigue, or other graft-related problems.
Death from all causes was similar between the TAG and
open surgical groups (Fig 2). Over 60 months, there were
45 deaths in the TAG group and 31 deaths in the surgical
cohort, resulting in respective survival rates of 68% and 67%
(log rank test P value  .433). Table I lists all causes of
death. Cardiac events, respiratory failure, stroke, and ma-
lignancy were the leading causes of death in both groups.
There were no known cases of aneurysm rupture in either
group although autopsy studies were rarely performed.
Adverse events. Major adverse events (MAE) after
DTA repair primarily occurred in the immediate postoper-
ative period, where 28% of TAG patients and 70% of
surgical controls had at least one MAE (P  .001). The
early advantage of fewer TAG MAEs continued through-
out follow-up, with 12-month MAE rates of 42% in the
TAG group and 77% in the surgical cohort (P  .001).
Kaplan-Meier analysis demonstrated a log-rank value of
P .001 for differences in the occurrence of MAEs be-
tween the TAG and surgical control patients out to 5 years,
with 57.9% of TAG and 78.7% of open patients having at
least one MAE (Fig 3). At 5 years, TAG patients were
significantly less likely to have had any bleeding, pulmo-
nary, renal, wound, or neurologic complications. TAG
patients were more likely to have had vascular complica-
tions (P  .004). Secondary procedures related to vascular
complications are listed below. There were no late instances
of renal failure. Cumulative MAE rates, which plot each
MAE rather than the number of patients who had any
MAE, showed that the average number of MAEs per pa-
1 year 2  years 3 years 4 years 5 years
95% C.I.
TAG
.488, .652 .419, .586 .375, .544 .366, .535 .279, .457
95% C.I.
Control
.152, .322 .142, .309 .132, .296 .132, .296 .132, .296
Fig 3. Freedom from major adverse events over time.Table I. Causes of death after descending thoracic
aneurysm repair out to 5 years
Aneurysm-related deaths
Cause of death
TAG cohort
(number of
patients)
Surgical controls
(number of
patients)
Respiratory failure 6
Stroke 1 3
Cardiac arrest 1 1
Aorto-esophageal fistula 1 1
Respiratory failure after
conversion
1
All-cause mortality
Cause of death TAG cohort Surgical controls
Cardiac arrest/MI 17 6
Cancer 4 2
Respiratory failure 5 8
Pneumonia 3 1
CHF 4
Stroke 3 4
Paraplegia 1
Sepsis 4 3
Pulmonary embolism 1
Ruptured AAA 1
Mesenteric ischemia 1
Trauma 1
Unknown 2 5
Total 45 31
MI, Myocardial infarction; CHF, congential heart failure; AAA, abdominal
tient at 5 years was 2.1 for TAG patients and 3.1 for surgical
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counted as MAEs.
Endoleaks, reinterventions and secondary proce-
dures. Endoleaks occurred in 10.6% of pivotal TAG
patients at some point during 5 years of follow-up (Table
II). Remarkably, very few were suspected to be type II from
intercostal arteries, and none of these were treated directly.
Most endoleaks were thought to be type I at the attach-
ment sites. Five TAG patients have had additional thoracic
reinterventions directly related to the DTA treated (Table
III). Three patients have required a total of five endovas-
cular reinterventions for endoleaks. These additional pro-
cedures took place from 45 to 1525 days after the original
repairs. One of the patients who had an endovascular
reintervention had a spine fracture in the original endopros-
thesis used. This patient also had a carotid-subclavian by-
pass to allow for TAG extension and developed hematoma
complications from this at the neck and groin. There have
been 20 spine fractures seen in 19 TAG patients, with only
one patient (described above) requiring treatment. No new
spine fractures were detected in any patients after 24
months of follow-up. One patient underwent conversion to
open repair after discovery of an aorto-esophageal fistula 73
days after TAG placement. He died of respiratory and
multisystem failure after the open procedure. The fifth
patient had an open arch aneurysm repair for type 1 en-
doleak and migration at 5 months. This case of migration
was the only one seen in 5 years, and was probably related
to poor proximal neck anatomy (migration incidence
0.7%). The rate of major, direct aneurysm-related reinter-
ventions in the TAG group at 5 years follow-up was 5/140
(3.6%). Reinterventions directly related to open aneurysm
repair occurred in two patients, with one having a proximal
anastomotic collection drained and one having debride-
ment and drain placement for an aorto-esophageal fistula.
The aneurysm reintervention rate was 2.1% for open con-
Fig 4. Cumulative major adverse events (MAEs) per patient over
time.trols.There were six patients in the TAG group who needed
secondary vascular procedures. Four of these took place on
postoperative day 1. Three were related to acute leg isch-
emia and one was an evacuation of a brachial artery hema-
toma. Another patient had hematoma complications after
carotid-subclavian bypass and extension of the TAG device.
The final patient had thrombosis of an iliofemoral conduit
on postoperative day 127 and underwent femoral to fem-
oral bypass.
The total number of TAG patients with at least one
secondary procedure following but not directly related to
the aneurysm repair was 21/140 (15.0%). There have been
30 patients with additional secondary procedures in the
surgical control group (31.91%). Most of these procedures
are related to perioperative complications (Table III).
There was one TAG patient who had a secondary proce-
dure not directly related to aneurysm treatment more than
30 days after the DTA repair. This was a thrombosis of an
iliofemoral conduit and is described above. In the surgical
control group, there were six secondary procedures which
took place more than 30 days after DTA repair, five related
to wound issues, and one patient with axillary aneurysm
repairs. At 5 years, there were significantly fewer aneurysm-
related secondary procedures in the TAG group (P 
.011). Fig 5 shows all secondary procedures and reinterven-
tions at 5 years.
Sac diameter. Change in the aneurysm sac diameter
was assessed at each follow-up timepoint, and most aneu-
rysms were found to increase or decrease over time, with a
small percentage remaining stable out to 5 years (Table IV).
In the pivotal trial, 19% of patients at 5 years had 5 mm or
more of sac enlargement compared with a 1-month base-
line, and 50% had 5 mm of sac shrinkage. Between 9.1%
and 12.5% of all patients with sac enlargement were noted
to have endoleaks between 1 month and 60 months post-
operatively. The confirmatory patient cohort, treated with
the revised low-porosity TAG endograft, exhibited no sac
enlargement at 1 year (P .0548 vs earlier TAG patients at
1 year), and 2.9% exhibited 5 mm sac enlargement at 2
years (P  0.11 vs earlier TAG patients at 2 years) (Fig 6).
Further follow-up data is not yet available for the confirma-
tory arm. The currently available commercial device is the
low-porosity endograft.
Follow-up. TAG group follow-up was from 3 days to
66 months with a mean of 37 months. Surgical controls
were compared with this group with a follow-up of 1 day to
73 months, mean 33 months. Twenty-six percent of TAG
patients did not complete 5-year follow-up as they refused
or were lost to follow-up. This was the case for 33% of open
controls. These patients were followed for an average of 29
months (TAG) and 30 months (open). Death occurred in
32% of TAG and 33% of open controls during follow-up.
Thirty-six percent of TAG and 24.5% of open patients
completed the 5-year follow-up as outlined in the trial
protocol. Outside of the patients who died or were lost to
follow-up, there were a small percentage of patients who
missed appointments or had appointments that fell outside
of the accepted window for each timepoint. For example, a
JOURNAL OF VASCULAR SURGERY
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23 and 60 after the procedure, and only 123/140 patients
fell within this time window. Without this CT no sac size
change measurements could be conducted within the study
protocol. Although these patients were followed as thor-
oughly as possible depending on their compliance, they
were not counted as meeting protocol requirements.
DISCUSSION
This work represents the first long-term results in a
large patient population after thoracic endografting and in
comparison with an open repair cohort. We illustrate that
the significant perioperative advantages of the TAG tho-
racic device over open repair persist for more than 60
months after treatment. The advantages of the TAG system
over open DTA repair include significantly lower rates of
Table II. Endoleaks over time
Periop 1 mo 6 mo
Patients available for
follow-up
81 123 108
Patients with endoleaks 7 (8.6%) 10 (8.1%) 7 (6.5%
Type Ia 3 5 4
Type Ib 1 1 1
Type II 1 1 1
Type III 1 1 —
Type IV — — —
Indeterminate 1 2 1
Type Ia, Proximal attachment site; Type Ib, distal attachment site.
Table III. All secondary procedures and direct aneurysm
reinterventions, reported as number of patients affected.
Patients may have had more than one procedure
TAG Controls
All secondary procedures
Additional thoracic aortic procedures 3 2
Empyema/chest wall reconstruction 0 5
Procedures for minor wound complications 8 8
Lumbar drain placement 2 2
Tracheostomy 3 10
Endoscopy or laparotomy for GI issues related
to surgery
1 9
Evacuation retroperitoneal bleed 1 0
Cardiac conversion for atrial fibrillation 0 3
Surgery for vocal card paralysis 0 2
Placement dialysis catheter 1 1
Resection of ischemic bowel 0 1
Vascular reconstructions 6 0
Miscellaneous 0 4
Direct aneurysm reinterventions
Conversion/treatment of graft infection 1 1
Drainage of peri-anastomotic collection 1
Extension for endoleaks 3 0
Evacuation of hematoma after carotid-
subclavian bypass, repair of femoral
pseudoaneurysm after TAG extension (all
same patient as counted above)
1
Conversion for migration 1 0aneurysm-related deaths and major adverse events. An in-tegral component of the long-lasting efficacy of the TAG
has been the low incidence of graft-related complications,
including few endoleaks, low rates of reintervention, and 1
of 140 patients with migration. The higher rate of periop-
erative and late secondary procedures within the surgical
control group was surprising, and this was predominately
related to wound complications. This does illustrate, how-
ever, that open surgical patients do have continuing and
new problems related to DTA repair months and years after
the original surgery. TAG patients also had late complica-
tions, mostly related to endoleaks and therapy for these.
Also, there have been events related to comorbidities that
appear to have manifested early in the open group and later
in the TAG group. There have been no known ruptures in
patients treated with TAG devices in this trial. Finally, the
TAG phase II trial report is also significant in that the
excellent results obtained were from a variety of practitio-
ners across 17 institutions.
Despite these excellent results that persist to 5 years, we
12 mo 24 mo 36 mo 48 mo 60 mo
103 80 64 57 47
4 (3.9%) 5 (6.3%) 2 (3.1%) 3 (5.3%) 2 (4.3%)
1 1 — 1 1
1 1 2 2 —
1 1 — — 1
— 1 — — —
— — — — —
1 1 — — —
Fig 5. Freedom from reintervention in TAG and surgical controls
at 5 years.)saw no difference in overall survival between the treatment
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or endovascular treatment was approximately 60%, with a
4-year survival of approximately 70%. This is not signifi-
cantly different than 4-year survival rates after abdominal
EVAR as seen in the EVAR I and II trials.10 These survival
rates reflect the aged population and comorbidities seen in
aneurysm patients. Natural history studies have estimated a
14% annual rate of death, dissection, or rupture with a DTA
of greater than 6 cm.2 Additionally, since this is not a
randomized study, there was a trend toward more TAG
patients having a preoperative history of cardiac events. The
higher cardiac death rate in TAG patients vs open controls
after DTA probably is a reflection of the less invasive nature
of the surgery, with TEVAR allowing these patients to
survive longer with significant cardiac disease but having a
higher long-term cardiac mortality.
Previous single-center reports have detailed midterm
results after thoracic endografting. Ellozy5 described the
results of TAG and Talent endografts (Medtronic/AVE,
Santa Rosa, Calif) used out to 52 months (mean follow-up
15 months). This series of patients within a mixture of
clinical trials (26% treated with TAG devices and 74%
treated with Talent devices) showed a higher operative
mortality (6%) and a 6% rupture rate. At a mean follow-up
of 18 months, Criado showed a 2.1% mortality rate and
17% incidence of MAEs, with one rupture 60 days after
treatment using the Talent graft.6 Demers et al’s follow-up
out to 10 years (mean 4.5 years) showed an 11% rupture
rate overall and an approximate 20% reintervention rate at
48 months using a homemade device.7 These collective
results illustrate a trend toward ever-improving results as
commercial devices are available and practitioners gain
Table IV. Aneurysm sac size change over time in TAG gr
Change in aneurysm size
1 to 6 mo
(N  85)
1 to 12 mo
(N  87)
Decrease 31 (35%) 37 (43%)
No change 49 (56%) 41 (48%)
Increase 8 (8%) 8 (9%)
Fig 6. Original and modified low-porosity TAG endograft sac
shrinkage at 2 years.more experience.Results out to 5 years after the phase II TAG study
show improvement over the early TAG feasibility study
which enrolled patients from 1998 to 1999. In this early
study of device safety, 28 patients received the TAG device
and had an aneurysm-related mortality of 3.6%. Endoleaks
were noted in 21% of the patients at some time in follow-up,
and 32% of the recipients had a stent fracture. There was a
10.7% rate of reinterventions/conversions, but no reports
of rupture.11 The current study shows improvement over
these results in several areas, which speak to continuing
evolution of the TAG endograft. The revision of the TAG
device in 2004 and elimination of the spine of the graft has
significantly decreased late graft-related complications and
made following TAG endografts more straightforward.
In contrast to endoleaks seen after endovascular repair
of infrarenal aneurysms, the endoleaks seen after TAG
endografting were predominately type I. The overall rate of
endoleak was low, but the high incidence of attachment site
leaks reminds practitioners to be judicious in patient selec-
tion, vigilant with follow-up, and aggressive in treatment
when appropriate. In some regards, the preponderance of
attachment site leaks is welcome news, as extension of the
endoprosthesis is a less technically difficult solution, rather
than the more challenging and potentially dangerous pros-
pect of coiling intercostal vessels. Thus far in follow-up,
spine fractures have not been a major cause of endoleak,
with only one patient needing treatment.
Sac expansion continues to be an issue with Gore
endografts used prior to the introduction of the low-
porosity fabric. Both in the treatment of abdominal aneu-
rysms12 and this series, we see a significant number of
patients with sac expansion that is not related to endoleak.
Although there has yet to be reported an incidence of
rupture associated with sac expansion in the absence of
endoleak with the Gore prosthesis, continued sac enlarge-
ment is worrisome. The early results from the low porosity
TAG are encouraging, showing fewer than 3% of patients
with sac expansion at 2 years. These results are even more
dramatic in early analysis of infrarenal Gore Excluder use
with the low-porosity devices having significantly more sac
regression compared with original devices at 12 months.13
Longer follow-up will be needed to determine if these early
results are predictive of long-lasting sac shrinkage.
A final note should mention the difficulty seen in
complete follow-up for TAG patients. More than 25% of
TAG patients were lost to or refused follow-up during this
trial. This is a disturbingly high number, especially knowing
that dedicated teams of local and national coordinators
to 24 mo
N  71)
1 to 36 mo
(N  57)
1 to 48 mo
(N  50)
1 to 60 mo
(N  26)
2 (46%) 29 (53%) 23 (45%) 21 (50%)
9 (41%) 17 (31%) 17 (33%) 13 (31%)
9 (13%) 9 (16%) 11 (22%) 8 (19%)oup
1
(
3
2were working to ensure compliance with trial protocol.
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capacity for follow-up compliance into account prior to
performing TEVAR, and make sure that the patient is
aware of his/her responsibility in this regard. Additionally,
this could have had an effect on our overall results of open vs
endovascular repair, as it is possible that patients with
complications were lost to follow-up and never diagnosed.
However, it is important to note that there was also rela-
tively poor follow-up for the open surgical group, so addi-
tional problems with the open group could have been
undetected as well.
CONCLUSIONS
At 5 years follow-up, TAG thoracic endografting is a
safe and effective method of DTA repair and is superior to
open repair, with lower aneurysm-related death and major
adverse events rates. The rate of reintervention or second-
ary procedures after any DTA repair is higher after open
surgery compared with endografting. There have been no
instances in post-repair DTA rupture in either patient co-
hort, and the risk of endoleak or migration after TEVAR is
very low. Modification of the TAG device appears to have
significantly decreased the late morbidity related to frac-
tures within the TAG device and late sac expansion. Con-
tinued vigilant follow-up of the TEVAR population is
needed to monitor for late complications.
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